Altre lingue Kazia Therapeutics Limited

Azioni

KZIA

US48669G1058

Tempo differito Nasdaq Altri mercati azionari 15:31:19 01/07/2024			Variaz. 5gg	Var. 1 gen.
0,2351 ^USD	+2,84%		+4,03%	-46,51%

01/05	Kazia Therapeutics Limited riferisce il successo del completamento della Fase 1 dello studio clinico EVT801 nei pazienti affetti da cancro avanzato	CI
27/03	Kazia Therapeutics Limited riporta i risultati degli utili per il semestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER	27/06
Kazia Therapeutics : Appointment of Director Form 6 K	24/06
Kazia Therapeutics : Securities Purchase Agreement - Form 6-K	17/05
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS	01/05
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	01/05
Kazia Therapeutics : Purchase Agreement - Form 6-K	19/04
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	19/04
Kazia Therapeutics : Corporate Presentation	12/04
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/03
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	27/03
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	21/03
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	21/03
Kazia Therapeutics : EVT801 Progress Update Presentation	19/03
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	27/02
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	21/02
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	21/02
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Certain Warrants of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04/02
Certain Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04/02
Certain American Depositary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kazia Therapeutics Limited

Azioni

KZIA

US48669G1058

Altre lingue

Filtri